BeyondSpring

General Information
Business:

We are a global clinical stage biopharmaceutical company focused on the development of innovative cancer therapies. We are advancing our lead asset, Plinabulin, into a Phase 2/3 clinical trial for the reduction of docetaxel chemotherapy-induced severe, grade 4 neutropenia, a Phase 2/3 clinical trial for the prevention of non-docetaxel chemotherapy-induced severe, grade 4 neutropenia, and a Phase 3 clinical trial as an anticancer agent in combination with docetaxel in advanced NSCLC. Plinabulin has also entered the first of a number of planned Phase 1/2 clinical trials to investigate its therapeutic potential in combination with the immuno-oncology agent nivolumab.

Industry: PHARMACEUTICAL PREPARATIONS
Employees: 24
Founded: 2014
Contact Information
Address 28 Liberty Street, 39th Floor, New York, New York 10005, US
Phone Number (646) 305-6387
Web Address https://www.beyondspringpharma.com
View Prospectus: BeyondSpring
Financial Information
Market Cap $434.2mil
Revenues $0 mil (last 12 months)
Net Income $-10.5 mil (last 12 months)
IPO Profile
Symbol BYSI
Exchange NASDAQ
Shares (millions): 0.2
Price range $20.00 - $20.00
Est. $ Volume $3.5 mil
Manager / Joint Managers Rodman & Renshaw (a Unit of H.C. Wainwright & Co.)
CO-Managers -
Expected To Trade: 3/9/2017
Status: Priced
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change